Use of animal model of sepsis to evaluate novel herbal therapies

Journal of Visualized Experiments

Volumn , Issue 62, 2012, Pages

  Li, Wei ^a   Zhu, Shu ^a   Zhang, Yusong ^a   Li, Jianhua ^a   Sama, Andrew E ^a   Wang, Ping ^a   Wang, Haichao ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Cecal ligation and puncture; Cytokines; Experimental animal model of sepsis; Herbal therapies; HMGB1; Innate immune cells; Issue 62; Medicine

Indexed keywords

EID: 84860688160     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/3926     Document Type: Article

References (28)

1. Wichterman, K.A., Baue, A.E., & Chaudry, I.H. Sepsis and septic shock--a review of laboratory models and a proposal. J. Surg. Res. 29, 189-201 (1980).
2. Baker, C.C., Chaudry, I.H., Gaines, H.O., & Baue, A.E. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery. 94, 331-335 (1983).
3. Hubbard, W.J., et al. Cecal ligation and puncture. Shock. 24 Suppl. 1, 52-57 (2005).
4. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004).
5. Baggiolini, M. & Loetscher, P. Chemokines in inflammation and immunity. Immunol. Today. 21, 418-420 (2000).
6. Balkwill, F. Cytokines--soluble factors in immune responses. Curr. Opin. Immunol. 1, 241-249 (1988).
7. Wang, H., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285, 248-251 (1999).
8. Yang, H., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U.S.A. 101, 296-301 (2004).
9. Qin, S., et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203, 1637-1642 (2006).
10. Ray, A. & Dittel, B.N. Isolation of Mouse Peritoneal Cavity Cells. J. Vis. Exp. (35), e1488, DOI: 10.3791/1488 (2010).
11. Rendon-Mitchell, B., et al. IFN-gamma Induces High Mobility Group Box 1 Protein Release Partly Through a TNF-Dependent Mechanism. J. Immunol. 170, 3890-3897 (2003).
12. Li, W., et al. A Major Ingredient of Green Tea Rescues Mice from Lethal Sepsis Partly by Inhibiting HMGB1. PLoS ONE. 2, e1153 (2007).
13. Osuchowski, M.F., Welch, K., Siddiqui, J., & Remick, D.G. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177, 1967-1974 (2006).
14. Heuer, J.G., et al. Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit. Care. Med. 32, 1570-1578 (2004).
15. Bozza, F.A., et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit. Care. 11, R49 (2007).
16. Li, W., et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem. Pharmacol. 81, 1152-1163 (2011).
17. Beutler, B., Milsark, I.W., & Cerami, A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229, 869-871 (1985).
18. Tracey, K.J., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330, 662-664 (1987).
19. Eskandari, M.K., et al. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148, 2724-2730 (1992).
20. Ziegler, E.J., et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324, 429-436 (1991).
21. Ziegler, E.J., et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307, 1225-1230 (1982).
22. Abraham, E., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 273, 934-941 (1995).
23. Cohen, J. Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br. Med. Bull. 55, 212-225 (1999).
24. Dellinger, R.P., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36, 296-327 (2008).
25. Wang, H., Zhu, S., Zhou, R., Li, W., & Sama, A.E. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert. Rev. Mol. Med 10, e32 (2008).
26. Wang, H. et al. The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J. Nutr. 136, 360-365 (2006).
27. Li, W., et al. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J. Immunol. 178, 3856-3864 (2007).
28. Fukuyama, M., et al. Mixed bacterial infection model of sepsis in rabbits and its application to evaluate superantigen-adsorbing device. Blood Purif. 23, 119-127 (2005).